| Tasmea Limited (TEA) ORDINARY FULLY PAID |
Industrials |
$1,010 |
Acquisition of Future Engineering Group - Announcement
|
26 Aug 2024 9:18AM |
$1.640 |
$4.140 |
risen by
152.44%
|
|
TEA - Price-sensitive ASX Announcement
Full Release
Key Points
- Tasmea Limited is acquiring 100% of Future Engineering Group.
- Future Engineering Group includes Future Engineering & Communication Unit Trust, Future Power Pty Ltd, Rollwell Pty Ltd, and Westplant Pty Ltd.
- The acquisition will be completed on or about 30 August 2024.
- The acquisition price includes a cash payment of A$52.5 million, A$17.5 million in Tasmea shares, and 37.7% of NPAT generated by FEG for FY2025, FY2026, and FY2027.
- The acquisition is expected to deliver approximately 21% EPS accretion.
- FEG's key management will remain with the company under long-term agreements.
- Tasmea aims to benefit from electrification trends and growth opportunities through this acquisition.
- The acquisition aligns with Tasmea's strategy to support Australia's energy transition and expand its specialist trade skill services.
- The synergies expected from the acquisition include enhanced capabilities and new revenue streams across Tasmea's subsidiaries.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| IXUP Limited (IXU) ORDINARY FULLY PAID |
Information Technology |
- |
Trading Halt
|
26 Aug 2024 9:16AM |
$0.029 |
$0.009 |
fallen by
68.97%
|
|
IXU - Price-sensitive ASX Announcement
Full Release
Key Points
- IXUP Limited requested a trading halt on the ASX.
- The trading halt is pending an announcement related to a significant deployment of IXUP's technology by a project partner.
- The halt will remain until the earlier of normal trading on 28 August 2024 or the release of the announcement.
- The company is managing its continuous disclosure obligations.
- IXUP is a technology company focused on secure data analytics and has a suite of products for secure data collaboration.
- IXUP operates BetStop, the National Self Exclusion Register under contract with the Commonwealth Government of Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Clarity Pharmaceuticals Ltd (CU6) ORDINARY FULLY PAID |
Health Care |
$1,447 |
Changes to Board of Directors and Management Team
|
26 Aug 2024 9:16AM |
$6.720 |
$3.890 |
fallen by
42.11%
|
|
| Constellation Technologies Limited (CT1) ORDINARY FULLY PAID |
Information Technology |
$3 |
Appendix 4G
|
26 Aug 2024 9:16AM |
$0.002 |
$0.002 |
risen by
33.33%
|
|
| Constellation Technologies Limited (CT1) ORDINARY FULLY PAID |
Information Technology |
$3 |
2024 Corporate Governance Statement
|
26 Aug 2024 9:16AM |
$0.002 |
$0.002 |
risen by
33.33%
|
|
| Constellation Technologies Limited (CT1) ORDINARY FULLY PAID |
Information Technology |
$3 |
Appendix 4E and Annual Financial Report
|
26 Aug 2024 9:15AM |
$0.002 |
$0.002 |
risen by
33.33%
|
|
CT1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Constellation Technologies Limited reported a 12.24% increase in revenue to $1,346,072 for the year ended 30 June 2024.
- The company recorded a net loss of $121,666, an improvement from the previous year's loss of $177,991.
- The Food Safety & Compliance (FSC) Module in the Callisto Solutions suite saw significant acceptance and the first major contract with Compass Group.
- The company's cash reserves decreased to $823,290 from $1,097,336 in the previous year.
- Total equity for the year ended 30 June 2024 stood at $872,218.
- Key risks identified include customer economic demand and reliance on senior key personnel.
- No dividends were paid or proposed during the financial year.
- No significant changes in the state of affairs occurred other than those disclosed in the Chairman's letter and CEO report.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Vanadium Limited (AVL) ORDINARY FULLY PAID |
Materials |
$91 |
Call on Unquoted Partly Paid Shares
|
26 Aug 2024 9:15AM |
$0.014 |
$0.011 |
fallen by
25%
|
|
| EVT Limited (EVT) ORDINARY FULLY PAID |
Communication Services |
$2,794 |
Appendix 4G and Corporate Governance Statement
|
26 Aug 2024 9:15AM |
$11.030 |
$17.190 |
risen by
55.85%
|
|
| AMCIL Limited (AMH) ORDINARY FULLY PAID |
Financials |
$350 |
Update - Notification of buy-back - AMH
|
26 Aug 2024 9:15AM |
$1.145 |
$1.110 |
fallen by
3.06%
|
|
| Foresta Group Holding Limited (FGH) ORDINARY FULLY PAID |
Materials |
$24 |
Disposal of Outdated Chemical Extraction Equipment
|
26 Aug 2024 9:14AM |
$0.006 |
$0.009 |
risen by
50%
|
|
FGH - Price-sensitive ASX Announcement
Full Release
Key Points
- Essential Queensland Pty Ltd, a subsidiary of Foresta Group Holdings Limited, entered into an agreement to scrap outdated chemical extraction equipment in Rotorua, New Zealand.
- The equipment was purchased second-hand in May 2022 and dismantled by December 2022.
- The equipment was stored on site in Rotorua pending the development of the Company's flagship project in New Zealand.
- Thorough review and inspection revealed significant deterioration and safety risks, leading to the decision to scrap the equipment.
- The Board prioritized safety and determined that the outdated equipment posed significant safety and functional risks.
- The outdated equipment represented an unjustifiable financial liability, including insurance premiums and storage costs.
- The Company will receive NZD $208,580.10 (inclusive of GST) from the agreement.
- An impairment of approximately AUD $4,886,009 related to the equipment will be noted in the Company's annual report for the year ended 30 June 2024.
- The Company plans to purchase new, improved, and safe chemical extraction equipment for its New Zealand project, contingent on securing the necessary funding.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$76 |
ACW updated depression trial results and implications
|
26 Aug 2024 9:13AM |
$0.024 |
$0.024 |
fallen by
0%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical announced positive results from the XanaCIDD phase 2a trial on depression.
- Xanamem treatment showed consistent benefits on symptoms of depression.
- A 10mg dose of Xanamem is effective in controlling brain cortisol and has anti-depressant activity.
- MADRS depression score improvement was significant in five of six subgroups.
- Patient Global Impression of Severity (PGI-S) data corroborated MADRS findings.
- Xanamem showed a 50% higher rate of remission of depression at Week 10.
- Therapeutic effects of Xanamem were durable, lasting four weeks post-treatment.
- Xanamem’s mechanism involves the inhibition of the 11ß-HSD1 enzyme, reducing brain cortisol levels.
- The XanaCIDD trial was a double-blind, placebo-controlled, six-week trial in 167 patients.
- Actinogen is exploring the path forward for Xanamem in treating Major Depressive Disorder (MDD).
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Tryptamine Therapeutics Limited (TYP) ORDINARY FULLY PAID |
Health Care |
$47 |
Completion of patient dosing in maiden TRP-8803 trial
|
26 Aug 2024 9:11AM |
$0.020 |
$0.034 |
risen by
70%
|
|
TYP - Price-sensitive ASX Announcement
Full Release
Key Points
- Phase 1b study of TRP-8803 completed with 11 participants.
- Participants given IV-infusion of psilocin over 150 minutes.
- Study aimed to refine dosing and infusion rates for TRP-8803.
- Achieved precise blood levels of psilocin with an acceptable pharmacokinetic profile.
- Completion marks an important milestone for Tryptamine Therapeutics Limited.
- Safety Review Council review of all data is now underway.
- Results to be used for future patent applications.
- Positive results will support future trials using TRP-8803.
- TRP-8803 trials de-risked through successful Phase 2a trials using TRP-8802.
- Phase 2a trials showed significant reductions in binge eating and fibromyalgia symptoms.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Perpetual Credit Income Trust (PCI) ORDINARY UNITS FULLY PAID |
Financials |
$574 |
Dividend/Distribution - PCI
|
26 Aug 2024 9:11AM |
$1.115 |
$1.180 |
risen by
5.83%
|
|
| Imagion Biosystems Limited (IBX) ORDINARY FULLY PAID |
Health Care |
$1 |
Final Director's Interest Notice (MH)
|
26 Aug 2024 9:11AM |
$0.036 |
$0.015 |
fallen by
58.33%
|
|
| Kuniko Limited (KNI) ORDINARY FULLY PAID |
Materials |
$8 |
EU CRMA Strategic Project Application
|
26 Aug 2024 9:11AM |
$0.160 |
$0.090 |
fallen by
43.75%
|
|
| Frontier Energy Limited (FHE) ORDINARY FULLY PAID |
Utilities |
$108 |
Trading Halt
|
26 Aug 2024 9:11AM |
$0.455 |
$0.210 |
fallen by
53.85%
|
|
FHE - Price-sensitive ASX Announcement
Full Release
Key Points
- Frontier Energy Limited (ASX: FHE) requested an immediate trading halt for its ordinary shares.
- The trading halt is related to a proposed capital raising by the company.
- The halt will last until the commencement of normal trading on 28 August 2024 or the release of an announcement.
- Frontier Energy Limited is developing the Waroona Renewable Energy Project in Western Australia.
- The project includes a 120MW solar farm and an 80MW 4-hour battery, with potential for over 1GW based on connection capacity.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Charter Hall Long Wale REIT (CLW) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$3,118 |
Update - Notification of buy-back - CLW
|
26 Aug 2024 9:10AM |
$3.790 |
$4.390 |
risen by
15.83%
|
|
| GDI Property Group (GDI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$367 |
Tax components of the distribution
|
26 Aug 2024 9:09AM |
$0.620 |
$0.683 |
risen by
10.08%
|
|
| Incitec Pivot Limited (IPL) ORDINARY FULLY PAID |
Materials |
$4,827 |
Update - Notification of buy-back - IPL
|
26 Aug 2024 9:09AM |
$2.980 |
$2.590 |
fallen by
13.09%
|
|
| Metcash Limited (MTS) ORDINARY FULLY PAID |
Consumer Staple |
$4,405 |
Application for quotation of securities - MTS
|
26 Aug 2024 9:09AM |
$3.620 |
$4.010 |
risen by
10.77%
|
|
| Graincorp Limited (GNC) ORDINARY FULLY PAID CLASS A |
Consumer Staple |
$1,697 |
Update - Notification of buy-back - GNC
|
26 Aug 2024 9:08AM |
$8.600 |
$7.635 |
fallen by
11.22%
|
|
| GDI Property Group (GDI) FULLY PAID ORDINARY/UNITS STAPLED SECURITIES |
Real Estate |
$367 |
Annual Results Presentation
|
26 Aug 2024 9:08AM |
$0.620 |
$0.683 |
risen by
10.08%
|
|
| US Masters Residential Property Fund (URF) FULLY PAID UNITS STAPLED SECURITIES |
Real Estate |
$218 |
Update - Notification of buy-back - URF
|
26 Aug 2024 9:08AM |
$0.320 |
$0.315 |
fallen by
1.56%
|
|
| Djerriwarrh Investments Limited (DJW) ORDINARY FULLY PAID |
Financials |
$834 |
Application for quotation of securities - DJW
|
26 Aug 2024 9:08AM |
$3.070 |
$3.170 |
risen by
3.26%
|
|
| James Bay Minerals Limited (JBY) ORDINARY FULLY PAID |
Materials |
$21 |
Field exploration underway across the La Grande East Project
|
26 Aug 2024 9:07AM |
$0.115 |
$0.600 |
risen by
421.74%
|
|
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
